Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Shigeki Chiba(Hokkaido University), Masahisa Jinushi(Hokkaido University), Jacob V. Gorman(AbbVie (United States)), Hisaya Akiba(Juntendo University), Ichiro Kinoshita(Hokkaido University), John Colgan(University of Iowa), Hirotoshi Dosaka‐Akita(Hokkaido University Hospital), Yusuke Ohba(University of Tsukuba), Hideo Yagita∥(Juntendo University), Akinori Takaoka(Hokkaido University), Muhammad Baghdadi(Hokkaido University), Mitsuomi Hirashima(Weatherford College), Yoichiro Fujioka(Hokkaido University of Science), Toshimitsu Uede(Rutgers, The State University of New Jersey), Hironori Yoshiyama(Shimane University)
Cited by 832
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
|Annals of Oncology|2012|555
TDAG8 Is a Proton-sensing and Psychosine-sensitive G-protein-coupled Receptor
|Journal of Biological Chemistry|2004|262
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
|Proceedings of the National Academy of Sciences|2008|251